First Covid-19 Vaccine Trails Begin In AFRICA
Africa’s first participation in a COVID-19 vaccine trial started Wednesday as nervous volunteers received injections, while officials said the continent of 1.3 billion people cannot be left behind.
The large-scale trial of the vaccine developed at the University of Oxford in Britain is being conducted in South Africa, Britain and Brazil.
South Africa has nearly one-third of Africa’s confirmed cases with more than 106,000, including more than 2,100 deaths. The country late Tuesday reported its biggest one-day death toll of 111.
“I feel a little bit scared but I want to know what is going on with this vaccine so that I can tell my friends and others what is going on with the study,” one of the vaccine trial volunteers, Junior Mhlongo, said in Johannesburg.
The African continent now has nearly 325,000 cases as countries loosen restrictions under economic pressure from citizens who say they have to feed their families.
Shortages of testing materials and medical supplies remain a problem as Africa could become the world’s next hot spot.
The pandemic was delayed in Africa “but is picking up speed very quickly,” the Africa Centers for Disease Control and Prevention chief John Nkengasong said Wednesday, with a steep increase in the number of cases and deaths.
“Unless we act now, Africa is at risk of being left behind on the global vaccine,” he warned a continental discussion and urged that local manufacturing and scientific expertise play a key role.
Cameroon, Uganda, Tanzania, Kenya and South Africa all have highly developed clinical trial capabilities, said Salim Abdool Karim, chair of South Africa’s ministerial advisory committee for COVID-19.
Many other sub-Saharan African countries also have clinical trial capacity, said Daniel Bausch, director of the UK Public Health Rapid Support Team.